N/A
Completed N=25
Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer
Bladder Cancer · Low Testosterone Levels
Source: ClinicalTrials.gov NCT03063125 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
May 2021
Primary outcomePrimary: Number of Hypogonadism in Participants Based on Serum Testosterone 90 Days Post Radical — 6 participants
Summary
The purpose of this study is to examine the relationship between testosterone level changes around the time of radical cystectomy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Hypogonadism in Participants Based on Serum Testosterone 90 Days Post Radical |
6 | — |
| SECONDARY The Number of Hypogonadism in Participants Based on Serum Testosterone 30 Days Post Radical Cystectomy |
8 | — |
| SECONDARY The Number of Hypogonadism in Participants Based on Serum Testosterone Immediately Post Surgery Days Post Radical Cystectomy |
19 | — |
| SECONDARY The Number of Hypogonadism in Participants Based on Serum Testosterone at Baseline Days Post Radical Cystectomy |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of bladder cancer
- Scheduled to undergo radical cystectomy
Exclusion Criteria
- Evidence of advanced metastatic disease,
- Undergoing cystectomy for non-bladder primary malignancy or bladder cancer type other than urothelial cell
- History of breast or prostate cancer
- Polycythemia, cardiovascular thromboembolism, untreated obstructive sleep apnea, uncontrolled heart failure, or acute coronary event in the past six months
Data sourced from ClinicalTrials.gov (NCT03063125). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.